A Multicenter, Open-Label, Randomized, Parallel-Group, Active-Controlled Study to Assess the Efficacy and Safety of Brivaracetam Administered Intravenously as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Brivaracetam (Primary) ; Lorazepam
- Indications Epilepsy
- Focus Therapeutic Use
- Sponsors UCB Biopharma
- 07 Sep 2017 Planned End Date changed from 1 Jun 2018 to 1 Apr 2018.
- 07 Sep 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Apr 2018.
- 09 Feb 2017 Status changed from not yet recruiting to recruiting.